IL147716A0 - Highly purified cytokine activating factor and methods of use - Google Patents

Highly purified cytokine activating factor and methods of use

Info

Publication number
IL147716A0
IL147716A0 IL14771600A IL14771600A IL147716A0 IL 147716 A0 IL147716 A0 IL 147716A0 IL 14771600 A IL14771600 A IL 14771600A IL 14771600 A IL14771600 A IL 14771600A IL 147716 A0 IL147716 A0 IL 147716A0
Authority
IL
Israel
Prior art keywords
methods
highly purified
activating factor
cytokine activating
purified cytokine
Prior art date
Application number
IL14771600A
Other languages
English (en)
Original Assignee
Dcv Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dcv Inc filed Critical Dcv Inc
Publication of IL147716A0 publication Critical patent/IL147716A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/852—Sperm
    • Y10S530/853—Ovary; eggs; embryos

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL14771600A 1999-07-23 2000-07-19 Highly purified cytokine activating factor and methods of use IL147716A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14531799P 1999-07-23 1999-07-23
US19761900P 2000-04-14 2000-04-14
PCT/US2000/019643 WO2001007472A1 (en) 1999-07-23 2000-07-19 Highly purified cytokine activating factor and methods of use

Publications (1)

Publication Number Publication Date
IL147716A0 true IL147716A0 (en) 2002-08-14

Family

ID=26842849

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14771600A IL147716A0 (en) 1999-07-23 2000-07-19 Highly purified cytokine activating factor and methods of use

Country Status (18)

Country Link
US (2) US6420337B1 (es)
EP (1) EP1198475B1 (es)
JP (1) JP4763193B2 (es)
CN (1) CN1376163A (es)
AR (1) AR033340A1 (es)
AT (1) ATE290017T1 (es)
AU (1) AU778239B2 (es)
BR (1) BR0013043A (es)
CA (1) CA2379251A1 (es)
CO (1) CO5290297A1 (es)
DE (1) DE60018426T2 (es)
ES (1) ES2239019T3 (es)
IL (1) IL147716A0 (es)
MX (1) MXPA02000779A (es)
MY (1) MY125980A (es)
NZ (1) NZ516744A (es)
TW (1) TWI250164B (es)
WO (1) WO2001007472A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487465A4 (en) * 2002-02-11 2007-05-30 Arkion Life Sciences Llc CLEANED CYTOKIN-INHIBITING FACTOR
US20040005327A1 (en) * 2002-05-16 2004-01-08 Subramanian Iyer Immune T-cell stimulation
WO2006069779A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US20080071067A1 (en) * 2006-09-20 2008-03-20 Avigenics, Inc. Methods of purifying proteins from egg white
US7852810B1 (en) * 2007-01-03 2010-12-14 Sprint Spectrum L.P. Dynamic adjustment of forward-link frame-error-rate (FFER) target
US7813323B1 (en) 2007-06-13 2010-10-12 Sprint Spectrum L.P. Dynamic adjustment of reverse-link frame-error-rate (RFER) target based on reverse-link RF conditions
US8107988B1 (en) 2008-07-25 2012-01-31 Sprint Spectrum L.P. Conducting power control based on reverse-link RF conditions
AU2009289484B2 (en) * 2008-09-05 2014-10-23 Cardiopolymers, Inc Apparatus and method for capsule formation in tissue
US8477686B1 (en) 2009-09-10 2013-07-02 Sprint Spectrum L.P. Automatic increase of target frame error rate for duration based on call drop timer
US8290532B1 (en) 2010-04-19 2012-10-16 Sprint Spectrum L.P. Selectively conducting reverse-link power control and call admission control
US8537700B1 (en) 2010-04-19 2013-09-17 Sprint Spectrum L.P. Identifying and selectively controlling reverse-noise contribution on a per-access-terminal basis
CN104288769B (zh) * 2014-09-17 2017-09-29 陕西建华生物制药有限公司 一种西药外用膏剂及其制备方法
JP5894695B1 (ja) * 2015-05-25 2016-03-30 ホーユー株式会社 ウズラの卵アレルギーの抗原
US10632158B2 (en) 2016-06-23 2020-04-28 IgY Nutrition Use of a hyperimmune egg product to prevent and treat dysbiosis
WO2018148734A1 (en) 2017-02-13 2018-08-16 The United States Of America, As Represented By The Secretary Of Agriculture Hyperimmunized egg product for treatment of necrotic enteritis in poultry

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119279D0 (en) * 1991-09-10 1991-10-23 Ici Plc Modification of lignin synthesis in plants
WO1998028419A2 (en) * 1996-12-20 1998-07-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulation of vesicular release

Also Published As

Publication number Publication date
ATE290017T1 (de) 2005-03-15
US6420337B1 (en) 2002-07-16
ES2239019T3 (es) 2005-09-16
AR033340A1 (es) 2003-12-17
MY125980A (en) 2006-09-29
NZ516744A (en) 2004-01-30
TWI250164B (en) 2006-03-01
DE60018426T2 (de) 2006-05-11
JP2003506019A (ja) 2003-02-18
EP1198475A4 (en) 2003-05-14
EP1198475B1 (en) 2005-03-02
CO5290297A1 (es) 2003-06-27
WO2001007472A1 (en) 2001-02-01
EP1198475A1 (en) 2002-04-24
JP4763193B2 (ja) 2011-08-31
AU6110600A (en) 2001-02-13
BR0013043A (pt) 2002-04-30
MXPA02000779A (es) 2003-10-15
AU778239B2 (en) 2004-11-25
US20030143190A1 (en) 2003-07-31
CA2379251A1 (en) 2001-02-01
CN1376163A (zh) 2002-10-23
DE60018426D1 (de) 2005-04-07

Similar Documents

Publication Publication Date Title
EP1227821A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD FOR USE THEREOF
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
HK1048247A1 (en) Stable carotene-xanthophyll beadlet compositions and methods of use
AU6118001A (en) Combination therapeutic compositions and methods of use
IL148657A0 (en) Stent range transducers and methods of use
GB0210645D0 (en) Underreamer and method of use
HUP0200418A3 (en) Human cytokine as ligand of the zalpha receptor and uses thereof
IL130900A0 (en) Atropisomers of 3-aryl-4(3H)- quinazolinones and their use as ampa-receptor antagonsts
IL162328A0 (en) Adjustable chair and method of use
HK1043113A1 (zh) 端粒酶抑制劑及其使用方法
AU1616499A (en) Chemokine variants and methods of use
EP1183030A4 (en) PROCESS FOR THE PREPARATION AND ITS USE OF N-DESMETHYLZOPICLONE
IL147716A0 (en) Highly purified cytokine activating factor and methods of use
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
HUP0003206A3 (en) Methods of preparing and purifying 9-nitro-20-camptothecin
AU1334602A (en) Osteopontin-coated surfaces and methods of use
AU3623700A (en) Apoptosis inducing molecule ii and methods of use
PL352333A1 (en) Dihydrobenzodiazepines and use of same in treatment of dislipidemia
EP1161451A4 (en) HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE
AU2002363938A8 (en) Methods and use of motoneuronotropic factors
EP1086215A4 (en) PREPARATION AND USE OF HIGHER VACCINES
HUP9800146A3 (en) Thalidomide-derivatives and use of them
IL163926A0 (en) Crystal structure of phosphodiesterase 5 and use thereof
AU1660201A (en) Biglycan and related therapeutics and methods of use
EP1263935A4 (en) SCYTONEMINE AND METHODS OF USE